Prognostic importance of RUNX1 expression for head and neck adenoid cystic carcinoma

Autor(es)

Soares, Ciro Dantas ^{[1, 2]} ; de Caceres, Cinthia Veronica Bardalez Lopez ^[1] ; Rodrigues-Fernandes, Carla Isabelly ^[1] ; de Lima Morais, Thayna Melo ^[1] ; de Almeida, Oslei Paes ^[1] ; de Carvalho, Maria Goretti Freire ^[2] ; Fonseca, Felipe Paiva ^[3]

Afiliação do(s) autor(es)

^[1] Univ Estadual Campinas, Piracicaba Dent Sch, Dept Oral Diag, Area Pathol, Piracicaba, SP - Brazil

^[2] Private Pathol Serv, Natal, RN - Brazil

^[3] Univ Fed Minas Gerais, Sch Dent, Dept Oral Surg & Pathol, Belo Horizonte, MG - Brazil

• Tipo de documento: Artigo Científico
• Fonte: ORAL DISEASES; v. 27, n. 2 JUL 2020.
• Citações Web of Science: 0

Resumo

Objective In the present study, we aimed to investigate the prognostic value of RUNX1 expression in 76 patients with adenoid cystic carcinoma (ACC). Materials and Methods All cases were arranged in tissue microarray blocks and submitted to immunohistochemistry against RUNX1. These results were statistically correlated with clinicopathologic features, including age, gender, tumour site, tumour size, lymph node status, AJCC clinical stage, distant metastasis, treatment, recurrences, follow-up, histologic pattern, vascular and neural invasion, all of which obtained from patient's medical records. Results RUNX1 was expressed in the nuclei of tumour cells, with a mean of 18.1% of positivity. Nuclear RUNX1 expression was significantly associated with AJCC clinical stage (p < .0001), solid histologic pattern (p < .0001), vascular invasion (p < .0001) and presence of local recurrence (p < .0001). Using univariate and multivariate analyses, RUNX1 nuclear expression was significantly associated with a lower disease-free survival (p p = .028, respectively) and disease-specific survival (p p = .018, respectively) rates. Conclusion In summary, RUNX1 nuclear expression may represent an indicator of unfavourable outcome for patients affected by head and neck ACC. (AU)

• Processo FAPESP: 15/25905-1 - Expressão de Akt, COX-2, RUNX1 e metaloproteinases em melanomas metastáticos e Prospecção biotecnológica de moléculas com atividade antitumoral
• Beneficiário: Ciro Dantas Soares
• Modalidade de apoio: Bolsas no Brasil - Doutorado
• Processo FAPESP: 17/16102-8 - Papel biológico de RUNX1, Akt, COX-2 e metaloproteinases no mecanismo de metástase em melanomas
• Beneficiário: Jacks Jorge Junior
• Modalidade de apoio: Auxílio à Pesquisa - Regular